Why is Balaxi Pharma falling/rising?

As of 12-Aug, Balaxi Pharmaceuticals Ltd is experiencing a decline in its stock price, currently at 48.57, which reflects a decrease of 0.53 or 1.08%. The stock's performance today is in line with its sector, and while it is trading higher than its 5-day and 20-day moving averages, it remains below the 50-day, 100-day, and 200-day moving averages. The stock has shown a 2.90% increase over the past week, contrasting with a 0.86% decline over the past month. However, it has significantly underperformed over the longer term, with a staggering 56.72% drop in the last year. The company's fundamentals indicate strong long-term strength with an average Return on Equity (ROE) of 30.97%, but it has also faced negative results recently, including a 70.93% fall in profit before tax and a 95.5% drop in profit after tax for the quarter ending June 25. Additionally, institutional investor participation has decreased by 7.16%, which may contribute to the stock's downward pressure.
In the broader market context, Balaxi Pharmaceuticals has underperformed against the benchmark, with the BSE500 showing a positive return of 3.56% year-to-date, while Balaxi's year-to-date return is a stark -32.83%. This consistent underperformance over the last three years, coupled with a significant decline in profits, has likely influenced investor sentiment negatively. The stock's liquidity remains adequate for trading, but the falling participation from institutional investors, who typically have more resources to analyze company fundamentals, suggests a lack of confidence in the stock's future performance.